NCT04766320View on ClinicalTrials.gov

Study on TIL for the Treatment of r/r Gynecologic Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 4, 2021

Primary Completion Date

December 4, 2022

Study Completion Date

January 31, 2025

Conditions
Gynecologic Cancer
Interventions
BIOLOGICAL

Tumor Infiltrating Lymphocytes (TIL)

Adoptive transfer of 1x10\^9-3x10\^11 autologous TILs to patients i.v. in 30-120 minutes.

Trial Locations (1)

200040

RECRUITING

Shanghai Tenth People's Hospital, Shanghai

All Listed Sponsors
collaborator

Shanghai Juncell Therapeutics

INDUSTRY

lead

Shanghai 10th People's Hospital

OTHER

NCT04766320 - Study on TIL for the Treatment of r/r Gynecologic Tumors | Biotech Hunter | Biotech Hunter